Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Jacqualyn Fouse has been named the next CEO of Agios Pharmaceuticals, a Cambridge, Mass.-based biotech firm. Effective Feb. 1, 2019, Fouse takes over for David Schenkein, who will become head of Agios’s board. Over the past decade, Schenkein has guided Agios as it shifted from a research organization to a biotech with two approved cancer drugs. Fouse, who was earlier president of Celgene, had been floated as a candidate for Gilead Sciences’ top job. Fouse will be one of the first women to helm a revenue-generating biotech firm.
This article has been sent to the following recipient: